Positive News SentimentPositive NewsNASDAQ:CLDX Celldex Therapeutics (CLDX) Stock Price, News & Analysis $20.35 -0.02 (-0.10%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.34 -0.01 (-0.02%) As of 05/23/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celldex Therapeutics Stock (NASDAQ:CLDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Celldex Therapeutics alerts:Sign Up Key Stats Today's Range$19.85▼$20.5150-Day Range$15.13▼$21.3652-Week Range$14.40▼$47.00Volume477,438 shsAverage Volume897,536 shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$53.90Consensus RatingModerate Buy Company OverviewCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Read More… Celldex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCLDX MarketRank™: Celldex Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 669th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingCelldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCelldex Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Celldex Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.48) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celldex Therapeutics is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celldex Therapeutics is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelldex Therapeutics has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.57% of the outstanding shares of Celldex Therapeutics have been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Celldex Therapeutics has recently increased by 2.62%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelldex Therapeutics does not currently pay a dividend.Dividend GrowthCelldex Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.57% of the outstanding shares of Celldex Therapeutics have been sold short.Short Interest Ratio / Days to CoverCelldex Therapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Celldex Therapeutics has recently increased by 2.62%, indicating that investor sentiment is decreasing. News and Social Media3.7 / 5News Sentiment1.66 News SentimentCelldex Therapeutics has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Celldex Therapeutics this week, compared to 5 articles on an average week.Search Interest1 people have searched for CLDX on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Celldex Therapeutics is held by insiders.Read more about Celldex Therapeutics' insider trading history. Receive CLDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Stock News HeadlinesCelldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growthMay 24 at 4:56 PM | investing.com2 'Strong Buy' Biotech Growth Stocks With Over 200% Upside PotentialMay 12, 2025 | msn.comBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 25, 2025 | Golden Portfolio (Ad)Celldex Therapeutics: Promising Pipeline and Strategic Developments Justify Buy RatingMay 12, 2025 | tipranks.comCelldex Therapeutics Q1 2025 Earnings: EPS of ($0. ...May 11, 2025 | gurufocus.comCelldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comDecoding Celldex Therapeutics Inc (CLDX): A Strategic SWOT InsightMay 9, 2025 | gurufocus.comCelldex Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | globenewswire.comSee More Headlines CLDX Stock Analysis - Frequently Asked Questions How have CLDX shares performed this year? Celldex Therapeutics' stock was trading at $25.27 at the start of the year. Since then, CLDX shares have decreased by 19.5% and is now trading at $20.35. View the best growth stocks for 2025 here. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.06. The biopharmaceutical company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative trailing twelve-month return on equity of 19.75%. When did Celldex Therapeutics' stock split? Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Celldex Therapeutics' major shareholders? Top institutional investors of Celldex Therapeutics include Wellington Management Group LLP (12.58%), Vanguard Group Inc. (5.87%), Eventide Asset Management LLC (5.66%) and Price T Rowe Associates Inc. MD (5.14%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi, Diane C Young and Sarah Cavanaugh. View institutional ownership trends. How do I buy shares of Celldex Therapeutics? Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celldex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings5/08/2025Today5/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:CLDX CIK744218 Webwww.celldex.com Phone(908) 454-7120Fax908-454-1911Employees150Year Founded1983Price Target and Rating Average Stock Price Target$53.90 High Stock Price Target$80.00 Low Stock Price Target$31.00 Potential Upside/Downside+164.9%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,430,000.00 Net Margins-1,544.32% Pretax Margin-1,544.32% Return on Equity-19.75% Return on Assets-18.86% Debt Debt-to-Equity RatioN/A Current Ratio24.27 Quick Ratio24.27 Sales & Book Value Annual Sales$7.56 million Price / Sales178.72 Cash FlowN/A Price / Cash FlowN/A Book Value$9.08 per share Price / Book2.24Miscellaneous Outstanding Shares66,384,000Free Float63,823,000Market Cap$1.35 billion OptionableOptionable Beta1.39 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:CLDX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.